Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strong in vivo antitumor activity in lymphoma.
about
The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.Preclinical evaluation of the BET bromodomain inhibitor BAY 1238097 for the treatment of lymphoma.BET bromodomain inhibitor birabresib in mantle cell lymphoma: in vivo activity and identification of novel combinations to overcome adaptive resistance
P2860
Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strong in vivo antitumor activity in lymphoma.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Bromodomain inhibitor OTX015 ( ...... ntitumor activity in lymphoma.
@en
Bromodomain inhibitor OTX015
@nl
type
label
Bromodomain inhibitor OTX015 ( ...... ntitumor activity in lymphoma.
@en
Bromodomain inhibitor OTX015
@nl
prefLabel
Bromodomain inhibitor OTX015 ( ...... ntitumor activity in lymphoma.
@en
Bromodomain inhibitor OTX015
@nl
P2093
P2860
P50
P356
P1433
P1476
Bromodomain inhibitor OTX015 ( ...... antitumor activity in lymphoma
@en
P2093
Anastasios Stathis
Andrea Rinaldi
Chiara Tarantelli
Elena Bernasconi
Elodie Odore
Esteban Cvitkovic
Eugenia Riveiro
Eugenio Gaudio
Maurilio Ponzoni
P2860
P304
58142-58147
P356
10.18632/ONCOTARGET.10983
P407
P577
2016-09-01T00:00:00Z